Norge - norsk - Statens legemiddelverk

ge healthcare as - albumin, humant, kolloidale partikler - pulver til inhalasjonsvæske til nebulisator, oppløsning - 0.5 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

paion deutschland gmbh - remimazolam besilate - bevisst sedasjon - psykoleptiske - remimazolam is indicated in adults for procedural sedation. remimazolam 50 mg is indicated in adults for intravenous induction and maintenance of general anaesthesia.

Den europeiske union - norsk - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - lupus erythematosus, systemisk - immunsuppressive - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.

Den europeiske union - norsk - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - deucravacitinib - psoriasis - immunsuppressive - treatment of moderate-to-severe plaque psoriasis in adults.

Den europeiske union - norsk - EMA (European Medicines Agency)

ratiopharm gmbh - desloratadin - rhinitis, allergic, perennial; urticaria; rhinitis, allergic, seasonal - antihistaminer til systemisk bruk, - desloratadine ratiopharm is indicated in adults for the relief of symptoms associated with:allergic rhinitischronic idiopathic urticaria as initially diagnosed by a physician.

Den europeiske union - norsk - EMA (European Medicines Agency)

sloan pharma s.a.r.l - botulinumtoksin type b - torticollis - muskelavslappende midler - neurobloc er indisert for behandling av cervikal dystoni (torticollis). se punkt 5.. 1 for data på effekt hos pasienter responsive / motstandsdyktig mot botulinumtoksin type a.

Den europeiske union - norsk - EMA (European Medicines Agency)

leo pharma a/s - brodalumab - psoriasis - immunsuppressive - kyntheum er indisert for behandling av moderat til alvorlig plakspsoriasis hos voksne pasienter som er kandidater til systemisk terapi.

Norge - norsk - Statens legemiddelverk

leo pharma (2) - kalsipotriolmonohydrat / betametasondipropionat - skum - 50 mikrog/ g / 0.5 mg/ g

Den europeiske union - norsk - EMA (European Medicines Agency)

almirall s.a - tildrakizumab - psoriasis - immunosuppressants, interleukin-hemmere, - ilumetri er indisert for behandling av voksne med moderat til alvorlig plakkpsoriasis som er kandidater for systemisk terapi.

Den europeiske union - norsk - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunsuppressive - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.